15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
1 citations
,
November 2002 in “Journal of dermatology” The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
October 2022 in “Amplla Editora eBooks”
13 citations
,
June 2015 in “International Journal of Dermatology” Patients with hair loss are much more likely to have body dysmorphic disorder than general dermatology patients.
57 citations
,
August 1997 in “Pediatrics International” VDDR I and II are genetic disorders affecting vitamin D use, causing rickets, with VDDR I treatable by vitamin D supplements and VDDR II needing high doses and calcium.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
April 2021 in “Journal of Investigative Dermatology” October 2025 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
4 citations
,
October 2011 in “International Journal of Dermatology” Bardet-Biedl syndrome may include under-recognized skin problems related to its metabolic disturbances.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
4 citations
,
May 2023 in “Pigment Cell & Melanoma Research” BMI1 is essential for preventing hair greying and maintaining hair color.
October 2024 in “Journal of the Endocrine Society” A rare genetic mutation causes resistance to vitamin D, leading to severe rickets and requiring high doses of calcium and vitamin D for treatment.
2 citations
,
July 2013 in “Journal of Life Sciences” A 2-year-old girl with a rare vitamin D disorder had rickets and hair loss, but treatment was ineffective due to poor compliance.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
5 citations
,
September 2014 in “Journal of Pharmaceutical Sciences”
7 citations
,
May 2019 in “European Journal of Human Genetics” BMP4-related anomalies can cause a wide range of eye, brain, and hand/foot problems, and new cases show this variability.
December 2025 in “International Journal of Dermatology” Björnstad syndrome can cause hair loss similar to androgenetic alopecia, and treatment with baricitinib and minoxidil may help.
211 citations
,
May 2013 in “Journal of Nutrition Health & Aging” MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
54 citations
,
December 2011 in “American Journal Of Pathology” A Gsdma3 mutation causes hair loss due to stem cell damage from skin inflammation.
July 2020 in “Research Square (Research Square)” Higher BMI, IGF-1, and DHEAS levels are linked to advanced bone age in young Chinese girls with early breast development.
16 citations
,
March 2011 in “Ophthalmic genetics” A patient with Birt-Hogg-Dubé Syndrome also had choroidal melanoma, suggesting the need for careful eyelid exams in such patients.
23 citations
,
January 2009 in “Veterinary Dermatology” The hepatitis B vaccine did not cause hair loss in the tested mice.
August 2025 in “Brazilian Journal of Hair Health” Hair-related body dysmorphic disorder is common in hair loss patients and needs early recognition for proper treatment.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
20 citations
,
September 2022 in “Journal of Biomedical Optics” PBM helps improve cell survival in 3D tissue engineering.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Patients with autoimmune blistering diseases experience a reduced quality of life, with the need for better measurement tools, especially for those with mucous membrane pemphigoid.
6 citations
,
August 2021 in “International Journal of Pharmaceutics” A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.